Immunology and the elusive AIDS vaccine

Developing a human immunodeficiency virus (HIV) vaccine is critical to end the global acquired immunodeficiency syndrome (AIDS) epidemic, but many question whether this goal is achievable. Natural immunity is not protective, and despite immunogenicity of HIV vaccine candidates, human trials have exclusively yielded disappointing results. Nevertheless, there is an indication that success may be possible, but this will be dependent on understanding the antiviral immune response in unprecedented depth to identify and engineer the types of immunity required. Here we outline fundamental immunological questions that need to be answered to develop a protective HIV vaccine, and the immediate need to harness a much broader scientific community to achieve this goal.

[1]  E. Wherry,et al.  Redefining Chronic Viral Infection , 2009, Cell.

[2]  C. Moore,et al.  Evidence of HIV-1 Adaptation to HLA-Restricted Immune Responses at a Population Level , 2002, Science.

[3]  F. Bushman,et al.  The Macaque Gut Microbiome in Health, Lentiviral Infection, and Chronic Enterocolitis , 2008, PLoS pathogens.

[4]  D. McGavern,et al.  IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection , 2008, The Journal of experimental medicine.

[5]  D. Brooks,et al.  Critical Role for CD4+ T Cells in Controlling Retrovirus Replication and Spread in Persistently Infected Mice , 1998, Journal of Virology.

[6]  Philip R. Johnson,et al.  Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys , 2009, Nature Medicine.

[7]  E. Rosenberg,et al.  Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction , 2007, Nature Immunology.

[8]  D. Burton,et al.  Fc receptor but not complement binding is important in antibody protection against HIV , 2007, Nature.

[9]  Amy S. Espeseth,et al.  Host Cell Factors in HIV Replication: Meta-Analysis of Genome-Wide Studies , 2009, PLoS pathogens.

[10]  Pascal Poignard,et al.  Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques , 2009, Nature Medicine.

[11]  H. Virgin,et al.  Immune Control of the Number and Reactivation Phenotype of Cells Latently Infected with a Gammaherpesvirus , 2002, Journal of Virology.

[12]  Bette T. Korber,et al.  Envelope-Constrained Neutralization-Sensitive HIV-1 After Heterosexual Transmission , 2004, Science.

[13]  D. Montefiori,et al.  Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys , 2008, Nature.

[14]  M. Malim,et al.  The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif , 2003, Nature Medicine.

[15]  G. Freeman,et al.  IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection , 2008, Proceedings of the National Academy of Sciences.

[16]  A. Wald,et al.  Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation , 2007, The Journal of experimental medicine.

[17]  B. Chesebro,et al.  Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[18]  David Heckerman,et al.  Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients , 2008, The Journal of experimental medicine.

[19]  N. Nagelkerke,et al.  Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya , 1996, The Lancet.

[20]  S. Rowland-Jones,et al.  Maintenance of HIV-Specific CD4+ T Cell Help Distinguishes HIV-2 from HIV-1 Infection1 , 2006, The Journal of Immunology.

[21]  Ashley T. Haase,et al.  Targeting early infection to prevent HIV-1 mucosal transmission , 2010, Nature.

[22]  Philip J. R. Goulder,et al.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression , 2006, Nature.

[23]  U. Dittmer,et al.  Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[24]  C. Van Lint,et al.  CpG methylation controls reactivation of HIV from latency , 2010, Retrovirology.

[25]  R. Balderas,et al.  Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction , 2006, Nature Medicine.

[26]  Todd M. Allen,et al.  Transmission and Long-Term Stability of Compensated CD8 Escape Mutations , 2008, Journal of Virology.

[27]  Phillip I. Tarr,et al.  Metagenomic Analysis of Human Diarrhea: Viral Detection and Discovery , 2008, PLoS pathogens.

[28]  A. Iwasaki,et al.  CTL mobilization to virus-infected tissue requires CD4+ T cell help , 2009, Nature.

[29]  Donald K Carter,et al.  HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis , 2008, The Lancet.

[30]  M. Oberste,et al.  Identification of Enteroviruses in Naturally Infected Captive Primates , 2008, Journal of Clinical Microbiology.

[31]  I. Wilson,et al.  HIV-1 and influenza antibodies: seeing antigens in new ways , 2009, Nature Immunology.

[32]  B Romanowski,et al.  Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2009, The Lancet.

[33]  Amalio Telenti,et al.  Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1 , 2007, Nature Genetics.

[34]  Richard T. Wyatt,et al.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals , 2009, Nature.

[35]  A. Urisman.  Viral detection and discovery using DNA microarrays , 2007 .

[36]  Michael G Hudgens,et al.  Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. , 2005, The Journal of infectious diseases.

[37]  R. Ahmed,et al.  mTOR regulates memory CD8 T cell differentiation , 2009, Nature.

[38]  Eric J. Arts,et al.  Variable Fitness Impact of HIV-1 Escape Mutations to Cytotoxic T Lymphocyte (CTL) Response , 2009, PLoS pathogens.

[39]  D. Burton,et al.  Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers , 2009, PLoS pathogens.

[40]  G. Kassiotis,et al.  Race between Retroviral Spread and CD4+ T-Cell Response Determines the Outcome of Acute Friend Virus Infection , 2009, Journal of Virology.

[41]  Alan S. Perelson,et al.  The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection , 2009, The Journal of experimental medicine.

[42]  Eva K. Lee,et al.  Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans , 2009, Nature Immunology.

[43]  D. Littman,et al.  Relief of Preintegration Inhibition and Characterization of Additional Blocks for HIV Replication in Primary Mouse T Cells , 2008, PloS one.

[44]  David W. Haas,et al.  HLA-Associated Immune Escape Pathways in HIV-1 Subtype B Gag, Pol and Nef Proteins , 2009, PloS one.

[45]  K. Sauer,et al.  IL-21 Is Required to Control Chronic Viral Infection , 2009, Science.

[46]  Susun Bellew,et al.  Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2010 .

[47]  A. Haase,et al.  Availability of activated CD4+ T cells dictates the level of viremia in naturally SIV-infected sooty mangabeys. , 2008, The Journal of clinical investigation.

[48]  Wei Wang,et al.  Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals , 2008, The Journal of experimental medicine.

[49]  R. Baric,et al.  Immune Mechanisms Responsible for Vaccination against and Clearance of Mucosal and Lymphatic Norovirus Infection , 2008, PLoS pathogens.

[50]  Christos J. Petropoulos,et al.  Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus , 2006, The Journal of experimental medicine.

[51]  M. Malim,et al.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein , 2002, Nature.

[52]  Thomas Gebhardt,et al.  Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus , 2009, Nature Immunology.

[53]  B. Fields.  AIDS: time to turn to basic science , 1994, Nature.

[54]  M. Diamond,et al.  Herpesvirus latency confers symbiotic protection from bacterial infection , 2007, Nature.

[55]  E. Zúñiga,et al.  Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo. , 2009, Immunity.

[56]  R. Siliciano,et al.  A Simian Immunodeficiency Virus-Infected Macaque Model To Study Viral Reservoirs That Persist during Highly Active Antiretroviral Therapy , 2009, Journal of Virology.

[57]  J. Brenchley,et al.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Retrovirology.

[58]  L. Picker,et al.  Effector-memory T cell responses are associated with protection of rhesus monkeys from mucosal SIV challenge , 2009, Nature Medicine.

[59]  T. Pierson,et al.  Maturation of West Nile Virus Modulates Sensitivity to Antibody-Mediated Neutralization , 2008, PLoS pathogens.

[60]  Todd M. Allen,et al.  HLA-B57/B*5801 Human Immunodeficiency Virus Type 1 Elite Controllers Select for Rare Gag Variants Associated with Reduced Viral Replication Capacity and Strong Cytotoxic T-Lymphocyte Recognition , 2009, Journal of Virology.

[61]  L. Picker,et al.  Profound CD4+/CCR5+ T cell expansion is induced by CD8+ lymphocyte depletion but does not account for accelerated SIV pathogenesis , 2009, The Journal of experimental medicine.

[62]  B. Walker,et al.  Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. , 2007, Immunity.

[63]  G. Freeman,et al.  Enhancing SIV-Specific Immunity In Vivo by PD-1 Blockade , 2008, Nature.

[64]  Wei Lu,et al.  Therapeutic dendritic-cell vaccine for chronic HIV-1 infection , 2004, Nature Medicine.

[65]  G. Freeman,et al.  Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.

[66]  J. Piaget,et al.  Coordination of Early Protective Immunity to Viral Infection by Regulatory T Cells , 2008 .

[67]  Alessandro Sette,et al.  Selection, Transmission, and Reversion of an Antigen-Processing Cytotoxic T-Lymphocyte Escape Mutation in Human Immunodeficiency Virus Type 1 Infection , 2004, Journal of Virology.

[68]  Norman L. Letvin,et al.  T-Cell Vaccine Strategies for Human Immunodeficiency Virus, the Virus with a Thousand Faces , 2009, Journal of Virology.

[69]  Frank Y. S. Chuang,et al.  Quantitative 3D Video Microscopy of HIV Transfer Across T Cell Virological Synapses , 2009, Science.

[70]  J J Goedert,et al.  HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study. , 1994, Journal of acquired immune deficiency syndromes.

[71]  A. Perelson,et al.  Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection , 2009, The Journal of experimental medicine.

[72]  Todd M. Allen,et al.  Structural and Functional Constraints Limit Options for Cytotoxic T-Lymphocyte Escape in the Immunodominant HLA-B27-Restricted Epitope in Human Immunodeficiency Virus Type 1 Capsid , 2008, Journal of Virology.

[73]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[74]  A. Iwasaki,et al.  CTL mobilization to virus-infected tissue requires CD4+ T cell help , 2009, Nature.

[75]  Scott N. Mueller,et al.  Enhancing therapeutic vaccination by blocking PD-1–mediated inhibitory signals during chronic infection , 2008, The Journal of experimental medicine.

[76]  A. Zajac,et al.  A Vital Role for Interleukin-21 in the Control of a Chronic Viral Infection , 2009, Science.

[77]  Tongqing Zhou,et al.  Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120 , 2009, Science.

[78]  B. Chesebro,et al.  Apobec3 Encodes Rfv3, a Gene Influencing Neutralizing Antibody Control of Retrovirus Infection , 2008, Science.

[79]  Dan R. Littman,et al.  Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria , 2009, Cell.

[80]  D. Watkins,et al.  Not All Cytokine-Producing CD8+ T Cells Suppress Simian Immunodeficiency Virus Replication , 2006, Journal of Virology.

[81]  Todd M. Allen,et al.  Differential Neutralization of Human Immunodeficiency Virus (HIV) Replication in Autologous CD4 T Cells by HIV-Specific Cytotoxic T Lymphocytes , 2009, Journal of Virology.

[82]  S. Hammer,et al.  HIV Vaccine Research: The Way Forward , 2008, Science.

[83]  James Theiler,et al.  Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants , 2007, Nature Medicine.

[84]  D. Douek,et al.  Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts , 2009, Nature Medicine.

[85]  Bin Li,et al.  HLA-B57/B*5801 Human Immunodeficiency Virus Type 1 Elite Controllers Select for Rare Gag Variants Associated with Reduced Viral Replication Capacity and Strong Cytotoxic T-Lymphotye Recognition , 2008, Journal of Virology.

[86]  Joep Lange,et al.  The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. , 2008, The Journal of clinical investigation.

[87]  David Heckerman,et al.  CD8+ T-cell responses to different HIV proteins have discordant associations with viral load , 2007, Nature Medicine.

[88]  Thomas F. Tedder,et al.  Innate and Adaptive Immunity Cooperate Flexibly to Maintain Host-Microbiota Mutualism , 2009, Science.

[89]  Hui Li,et al.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.

[90]  R. Ahmed,et al.  CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection , 1994, Journal of virology.

[91]  M. Vignuzzi,et al.  Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population , 2006, Nature.

[92]  Z. Grossman,et al.  HIV preferentially infects HIV-specific CD4+ T cells , 2002, Nature.

[93]  Anantha Marri,et al.  Complement Activation Is Required for Induction of a Protective Antibody Response against West Nile Virus Infection , 2005, Journal of Virology.

[94]  P. Bieniasz,et al.  Human immunodeficiency virus, restriction factors, and interferon. , 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[95]  Devan V Mehrotra,et al.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.

[96]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[97]  K. Tyler,et al.  Protective anti-reovirus monoclonal antibodies and their effects on viral pathogenesis , 1993, Journal of virology.

[98]  Susan Moir,et al.  B cells in HIV infection and disease , 2009, Nature Reviews Immunology.

[99]  Ronald S Veazey,et al.  A macaque model of HIV-1 infection , 2009, Proceedings of the National Academy of Sciences.

[100]  H. Virgin,et al.  Antibody-Independent Control of γ-Herpesvirus Latency via B Cell Induction of Anti-Viral T Cell Responses , 2006, PLoS pathogens.

[101]  R. Koup,et al.  PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection , 2006, The Journal of experimental medicine.

[102]  J. Weber,et al.  IL-21R on T Cells Is Critical for Sustained Functionality and Control of Chronic Viral Infection , 2009, Science.

[103]  D. Watkins,et al.  Vaccine-Induced Cellular Responses Control Simian Immunodeficiency Virus Replication after Heterologous Challenge , 2009, Journal of Virology.

[104]  D. Montefiori,et al.  Protection by Live, Attenuated Simian Immunodeficiency Virus against Heterologous Challenge , 1999, Journal of Virology.

[105]  K. Mansfield,et al.  Trafficking of Antigen-Specific CD8+ T Lymphocytes to Mucosal Surfaces following Intramuscular Vaccination1 , 2008, The Journal of Immunology.